The estimated Net Worth of Lynn Seely is at least 6.26 百万$ dollars as of 19 June 2020. Lynn Seely owns over 1,312 units of Myovant Sciences Ltd stock worth over 35,398$ and over the last 9 years he sold MYOV stock worth over 0$. In addition, he makes 6,222,670$ as Principal Executive Officer、 Director at Myovant Sciences Ltd.
Lynn has made over 1 trades of the Myovant Sciences Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,312 units of MYOV stock worth 35,398$ on 19 June 2020.
The largest trade he's ever made was exercising 1,312 units of Myovant Sciences Ltd stock on 19 June 2020 worth over 35,398$. On average, Lynn trades about 73 units every 0 days since 2016. As of 19 June 2020 he still owns at least 1,312 units of Myovant Sciences Ltd stock.
You can see the complete history of Lynn Seely stock trades at the bottom of the page.
Dr. Lynn Seely M.D. serves as Principal Executive Officer, Director of the Company. She served as President of the Company. Dr. Seely has served as a member of the Board since May 2016 and as our Principal Executive Officer and the President and Chief Executive Officer of Myovant Sciences, Inc., our wholly owned subsidiary, since May 2016. From March 2005 to October 2015, Dr. Seely served as Chief Medical Officer of Medivation, Inc., a biopharmaceutical company, where she served on the Executive Committee and led the development of XTANDI® for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely was responsible for building the clinical organization at Medivation, Inc., as well as the regulatory, quality, project management, medical affairs and biologics manufacturing functions. Dr. Seely previously served as Vice President of Clinical Development at Anesiva, Inc. (formerly Corgentech), a biopharmaceutical company, and at Cytyc Health Corporation, a medical device company. In addition, she currently serves as a director of Blueprint Medicines Corporation, a biotechnology company. Dr. Seely received her B.A. in Journalism from the University of Oklahoma and her M.D. from the University of Oklahoma College of Medicine and completed her residency in internal medicine at Yale-New Haven Hospital. After serving as Chief Resident in Internal Medicine at Yale University School of Medicine, she completed her basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego. Seely’s position as our Principal Executive Officer and her extensive prior experience in the biopharmaceutical industry qualify her to serve on the Board.
As the Principal Executive Officer、 Director of Myovant Sciences Ltd, the total compensation of Lynn Seely at Myovant Sciences Ltd is 6,222,670$. There are no executives at Myovant Sciences Ltd getting paid more.
Lynn Seely is 61, he's been the Principal Executive Officer、 Director of Myovant Sciences Ltd since 2019. There are 3 older and 9 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.
Lynn's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over 5,780,890$ worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth 2,001,605,371$ . The most active insiders traders include Sciences Ltd. Roivant、Global Investors Lp Viking ...、Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of 25,106,967$. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth 1,393,178,400$.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: